BioLineRx Ltd. (BLRX) stock
BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 3/30
$1.12−0.03 (-2.61%)
Close on Nov 17, 2026Market cap $4.87MP/E –Yield –
BioLineRx gross margin
Gross margin is gross profit as a percentage of revenue.
For fiscal 2025 it was 80.5%, against 68.0% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 80.5% | +12.5 |
| FY2024 | Dec 31, 2024 | 68.0% | +44.9 |
| FY2023 | Dec 31, 2023 | 23.1% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 79.9% | – |
| Q2 FY2025 | Jun 30, 2025 | 76.3% | – |
| Q2 FY2024 | Jun 30, 2024 | 83.4% | – |
See a number that looks wrong?